Literature DB >> 15880563

Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.

Alan P Venook1.   

Abstract

Substantial effort has focused on the development of novel targeted agents for treating patients with late-stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma. Copyright 2005 American Cancer Society.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15880563     DOI： 10.1002/cncr.21123

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  28 in total

1.  KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.

Authors:  Marta Herreros-Villanueva; Maximiliano Rodrigo; Manuel Claver; Pilar Muñiz; Enrique Lastra; Carlos García-Girón; Maria Jesus Coma del Corral
Journal:  Mol Biol Rep       Date:  2010-06-20       Impact factor: 2.316

2.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

3.  KRAS assay selection: sensitivity and accuracy in clinical application.

Authors:  Marta Herreros-Villanueva; Gaurav Aggarwal
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

4.  Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.

Authors:  Maria Arcila; Christopher Lau; Khedoudja Nafa; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

5.  Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation.

Authors:  Guofeng Xie; Zhongsheng Peng; Jean-Pierre Raufman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-23       Impact factor: 4.052

6.  β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

Authors:  Shanthi Ganesh; Xue Shui; Kevin P Craig; Martin L Koser; Girish R Chopda; Wendy A Cyr; Chengjung Lai; Henryk Dudek; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2017-12-27       Impact factor: 6.261

Review 7.  Polyclonal tumors in the mammalian intestine: are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression?

Authors:  Richard B Halberg; William F Dove
Journal:  Cell Cycle       Date:  2007-01-28       Impact factor: 4.534

8.  TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.

Authors:  Marta Herreros-Villanueva; Pilar Muñiz; Carlos García-Girón; Mónica Cavia-Saiz; María J Coma del Corral
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

9.  Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; R Wong
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

10.  Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients.

Authors:  Jing Gao; Ting-Ting Wang; Jing-Wei Yu; Yan-Yan Li; Lin Shen
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.